TrialBlood cancer journal2024

Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.

Surbhi Sidana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.